Recent 8-K filings for DWTX

• May 14, 2026, 8:50 AM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Dogwood Q1 net loss $5.0M; Halneuron Phase 2b data due fall 2026

  Net loss of $5.0M ($0.15 per share) vs $12.2M ($8.45) in Q1 2025; R&D $2.7M, G&A $2.4M.

• March 26, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Dogwood provides HALT-CINP trial update; $12.5M raised, SP16 IND filed

  145 patients recruited in Halneuron Phase 2b HALT-CINP study; final data expected fall 2026.

• March 18, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Dogwood Therapeutics Q4 loss $3.8M; Halneuron Phase 2b >50% enrolled, top-line Q3 2026

  Net loss Q4 2025 $3.8M ($0.26/share) vs $8.2M ($6.29) in Q4 2024; full year loss $35.5M ($7.13).

• January 20, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Dogwood Therapeutics reports Halneuron Phase 2b progress, new SP16 license, and 2026 milestones

  Over 100 patients enrolled in Halneuron Phase 2b HALT-CINP study; interim analysis determined final sample size and methodology.

• January 13, 2026, 6:59 PM ET other material materiality 0.75 positive item 1.01item 1.02item 3.02item 7.01item 9.01 ◈ Material Agreements ×4

  Dogwood Therapeutics raises $12.5M upfront; potential $14.4M from warrant exercise

  Gross proceeds of $12.5M from registered direct offering and concurrent private placement; potential additional $14.4M upon warrant exercise.

• November 21, 2025, 6:59 PM ET other material materiality 0.65 neutral item 5.02item 5.07item 9.01

  Dogwood Therapeutics completes business combination with Sealbond; approves equity plan adding 2.78M shares

  Stockholders approved the potential issuance of common stock upon conversion of Series A, A-1, and A-2 preferred stock.

• November 6, 2025, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Dogwood Therapeutics Q3 2025 net loss $15.7M; cash runway through Q1 2026

  Net loss per share of $8.20 vs. $2.05 in Q3 2024; R&D expenses surged to $14.5M from $0.5M.

• September 29, 2025, 7:59 PM ET M&A materiality 0.80 positive item 1.01item 5.03item 3.02item 3.03item 7.01item 9.01 ◈ Governance Changes

  Dogwood Therapeutics licenses SP16 for CIPN in all-stock deal; NCI funds Phase 1b

  Royalty-free global license from Serpin Pharma for SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN).

• August 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Dogwood Therapeutics Q2 net loss $3.8M; Halneuron Phase 2b interim data on track for Q4 2025

  Enrolled 52 patients in Halneuron Phase 2b CINP trial; low discontinuation rate of 5.8% due to adverse events.

• May 8, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Dogwood Therapeutics Q1 2025 net loss $12.2M; Halneuron Phase 2b dosing underway

  Net loss of $12.2M ($8.45 per share) vs $1.3M ($1.68) in Q1 2024; R&D spend rose to $2.4M.

• April 3, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Dogwood Therapeutics regains Nasdaq minimum equity compliance after $19.9M debt swap and $4.8M offering

  Regained compliance with Nasdaq minimum stockholders' equity requirement ($2.5M).

• March 31, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Dogwood Therapeutics Q4 2024 net loss $8.2M; cash $14.8M; Halneuron Phase 2b interim data expected Q4 2025

  Q4 2024 net loss $8.2M ($6.29/share) vs $1.1M ($1.43/share) in Q4 2023; FY net loss $12.9M ($12.52/share) vs $5.3M ($7.05/share).

• March 14, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  Dogwood Therapeutics prices $4.8M registered direct offering; funds operations through Q1 2026

  Sold 578,950 shares at $8.26 each for gross proceeds of approximately $4.8 million.

• March 12, 2025, 7:59 PM ET other material materiality 0.80 positive item 1.01item 5.03item 3.02item 3.03item 7.01item 9.01

  Dogwood converts $19.9M debt and interest to Series A-1 preferred equity

  $19.5M principal plus accrued interest ($19,926,891 total) exchanged for 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock.

• December 18, 2024, 6:59 PM ET other material materiality 0.65 negative item 9.01

  Pharmagesic financials: $4.9M loss, $82M deficit; Dogwood provides $19.5M funding

  Pharmagesic (Holdings) Inc. (acquired Oct 7) had $4.9M net loss in 2023; no revenue; R&D costs $3.9M.

• November 21, 2024, 6:59 PM ET regulatory materiality 0.85 negative item 3.01

  Dogwood Therapeutics receives Nasdaq delisting notice for low stockholders' equity

  Stockholders' equity fell below $2.5M minimum per Q3 2024 10-Q; delisting risk under Nasdaq Rule 5550(b)(1).

• November 7, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Dogwood Therapeutics Q3 net loss $2.3M; cash runway depends on $3M Feb 2025 tranche

  Net loss $2.3M ($2.05/share) vs $1.2M ($1.62) in Q3 2023; R&D and G&A expenses rose.

• October 30, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Dogwood Therapeutics regains Nasdaq compliance; phase 2a Long-COVID data expected mid-Nov

  Regained Nasdaq minimum bid price compliance; closing bid price >= $1.00 for 10 consecutive trading days.

• October 7, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 1.01item 5.03item 2.01item 3.02item 3.03item 5.02item 7.01item 8.01item 9.01 ◈ executive_change ×4

  Virios acquires Pharmagesic, receives $19.5M loan, appoints new board, changes name to Dogwood Therapeutics

  Acquired 100% of Pharmagesic from Sealbond; issued 211,383 common shares and ~2,108 Series A convertible preferred shares.

• June 12, 2024, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

  Virios Therapeutics granted Nasdaq exception until Oct 28, 2024 to regain $1.00 bid price compliance

  Nasdaq Hearing Panel grants exception until October 28, 2024 to meet minimum $1.00 bid price rule.

• May 7, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Virios receives Nasdaq deficiency notice for bid price; requests hearing to seek compliance extension

  Second Nasdaq letter received May 1, 2024 for failure to maintain $1.00 minimum bid price.

• February 29, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Virios reports FY2023 net loss $5.3M, down 57% YoY; FDA aligns on Long-COVID endpoint for IMC-2

  Net loss for FY2023 $5.3M ($0.28/share), down from $12.2M ($1.11/share) in FY2022.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

7 positive 7 negative 19 neutral

source · DWTX on sec.gov